rosiglitazone has been researched along with lysophosphatidic acid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Chun, J; Daviaud, D; Grès, S; Guigné, C; Pradère, JP; Saulnier-Blache, JS; Simon, MF; Valet, P; Wabitsch, M | 1 |
| Allison, P; Baker, DL; Bittman, R; Li, Z; Makarova, N; Parrill, A; Tigyi, G; Tsukahara, R; Tsukahara, T; Valentine, WJ; Yasuda, S; Yuan, H | 1 |
| Balazs, L; Cheng, Y; Farrar, P; Guo, H; Makarova, N; Shuyu, E; Tigyi, G; Tsukahara, R; Zhang, C | 1 |
| Du, X; Guo, S; Jiang, C; Li, X; Liu, J; Ma, Y; Mei, S; Sun, N; Tang, K; Wang, X; Zhao, D | 1 |
5 other study(ies) available for rosiglitazone and lysophosphatidic acid
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Blotting, Western; Carrier Proteins; Cell Differentiation; Cell Line; Cell Proliferation; Culture Media, Serum-Free; Down-Regulation; Fatty Acid-Binding Proteins; Glucose-6-Phosphate Isomerase; Glycoproteins; Humans; Hypoglycemic Agents; Lysophospholipids; Male; Mice; Mice, Knockout; Mice, Transgenic; Monocytes; Multienzyme Complexes; Oligonucleotides; Phosphodiesterase I; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoric Diester Hydrolases; PPAR gamma; Pyrophosphatases; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Transcription, Genetic; Triglycerides | 2005 |
Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.
Topics: Adenoviridae; Alanine; Animals; Benzophenones; Blotting, Western; Cell Line; Cell Line, Tumor; Cells, Cultured; Chlorocebus aethiops; Crystallography, X-Ray; Dose-Response Relationship, Drug; Gene Expression Regulation; Genes, Reporter; Humans; Hypoglycemic Agents; Kinetics; Ligands; Lipids; Lysophospholipids; Models, Chemical; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Oxygen; Plasmids; Point Mutation; PPAR gamma; Protein Binding; Protein Structure, Tertiary; Rats; Rosiglitazone; Thiazolidinediones; Transfection | 2006 |
Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.
Topics: Animals; Carotid Artery Injuries; Carotid Artery, Common; Gene Knockdown Techniques; Glycerophosphates; Hypoglycemic Agents; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones | 2009 |
18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Biological Products; Cardiotoxicity; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Fatty Acids; Heart; Hypoglycemic Agents; Lipids; Liver; Lysophospholipids; Male; Medicine, Chinese Traditional; Mice; Molecular Docking Simulation; PPAR gamma; Rosiglitazone | 2021 |